- Home
- MPB vs ORIC Comparison
MPB vs ORIC Comparison
Compare MPB & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MPB | ORIC |
|---|---|---|
| Founded | 1868 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 738.9M | 973.9M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | MPB | ORIC |
|---|---|---|
| Price | $32.35 | $8.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 12 |
| Target Price | ★ $37.00 | $19.50 |
| AVG Volume (30 Days) | 95.0K | ★ 1.5M |
| Earning Date | 01-21-2026 | 11-13-2025 |
| Dividend Yield | ★ 2.72% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.40 | N/A |
| Revenue | ★ $208,869,000.00 | N/A |
| Revenue This Year | $26.19 | N/A |
| Revenue Next Year | $28.25 | N/A |
| P/E Ratio | $13.48 | ★ N/A |
| Revenue Growth | ★ 20.73 | N/A |
| 52 Week Low | $22.50 | $3.90 |
| 52 Week High | $33.24 | $14.93 |
Technical Indicators
Market Signals| Indicator | MPB | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 69.46 | 20.00 |
| Support Level | $31.76 | $10.45 |
| Resistance Level | $32.62 | $12.50 |
| Average True Range (ATR) | 0.63 | 0.70 |
| MACD | 0.22 | -0.24 |
| Stochastic Oscillator | 79.52 | 1.33 |
Price Performance
Historical ComparisonAbout MPB Mid Penn Bancorp
Mid Penn Bancorp Inc operates in the financial services domain. It conducts commercial banking and trust business in the United States. Its range of services comprises mortgage and home equity loans, secured and unsecured consists and consumer loans, lines of credit, construction financing, farm loans, community development, local government loans, and various types of time and demand deposits.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.